Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 115,358,416
  • Shares Outstanding, K 253,719
  • Annual Sales, $ 11,020 M
  • Annual Income, $ -535,600 K
  • EBIT $ 3,993 M
  • EBITDA $ 4,201 M
  • 60-Month Beta 0.31
  • Price/Sales 10.02
  • Price/Cash Flow N/A
  • Price/Book 6.82

Options Overview Details

View History
  • Implied Volatility 33.81% (+2.82%)
  • Historical Volatility 31.44%
  • IV Percentile 79%
  • IV Rank 46.74%
  • IV High 47.19% on 04/08/25
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 2) 8.08 (1.79%)
  • Put/Call Vol Ratio 2.89
  • Today's Volume 2,476
  • Volume Avg (30-Day) 2,203
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 44,316
  • Open Int (30-Day) 41,696
  • Expected Range 442.34 to 458.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 4.41
  • Number of Estimates 9
  • High Estimate 4.77
  • Low Estimate 4.00
  • Prior Year 3.54
  • Growth Rate Est. (year over year) +24.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
443.12 +1.46%
on 01/05/26
487.52 -7.78%
on 01/07/26
-2.44 (-0.54%)
since 12/12/25
3-Month
403.16 +11.52%
on 11/04/25
487.52 -7.78%
on 01/07/26
+37.38 (+9.07%)
since 10/14/25
52-Week
362.50 +24.03%
on 08/11/25
519.68 -13.49%
on 03/14/25
+37.94 (+9.22%)
since 01/14/25

Most Recent Stories

More News
Here's What to Expect From Vertex Pharmaceuticals' Next Earnings Report

Vertex Pharmaceuticals is scheduled to post its fourth-quarter results soon, and analysts project a double-digit earnings growth

ABT : 123.60 (-0.56%)
XLV : 157.11 (+0.24%)
$SPX : 6,890.55 (-1.05%)
VRTX : 448.17 (-1.43%)
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 44th...

VRTX : 448.17 (-1.43%)
Stocks making big moves yesterday: Herbalife, Vertex Pharmaceuticals, Micron, Amkor, and Palantir Technologies

Stocks making big moves yesterday: Herbalife, Vertex Pharmaceuticals, Micron, Amkor, and Palantir Technologies

HLF : 15.88 (+1.73%)
MU : 332.22 (-1.75%)
VRTX : 448.17 (-1.43%)
AMKR : 48.15 (-7.31%)
PLTR : 174.94 (-2.25%)
Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why

Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why

VRTX : 448.17 (-1.43%)
Stock Index Futures Slip in Weak End to a Banner Year

March S&P 500 E-Mini futures (ESH26) are down -0.20%, and March Nasdaq 100 E-Mini futures (NQH26) are down -0.32% this morning, pointing to a weak start on Wall Street in the final trading session of 2025....

KLAC : 1,410.99 (-2.14%)
AMAT : 298.44 (-2.11%)
GOOGL : 332.83 (-0.93%)
META : 617.16 (-2.21%)
C : 110.96 (-4.59%)
MOH : 186.18 (+2.90%)
VRTX : 448.17 (-1.43%)
NKE : 65.48 (-1.24%)
SEPL.LN : 321.500 (+6.46%)
ESH26 : 6,929.25 (-1.04%)
ANGH : 3.60 (-1.64%)
NQH26 : 25,468.00 (-1.69%)
Stocks Fall Slightly in Thin Holiday Trade

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.14%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.25%. March E-mini...

C : 110.96 (-4.59%)
RARE : 23.91 (-0.83%)
HL : 24.06 (-1.03%)
SLB : 46.90 (+2.18%)
$IUXX : 25,304.53 (-1.70%)
ZNH26 : 112-165 (+0.22%)
OXY : 44.70 (+3.21%)
ESH26 : 6,929.25 (-1.04%)
FANG : 154.17 (+1.96%)
JBL : 240.34 (+0.83%)
$DOWI : 48,921.38 (-0.55%)
SPY : 686.89 (-0.99%)
Stocks Slip as Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) today is down -0.12%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.11%. March E-mini S&P futures...

C : 110.96 (-4.59%)
RARE : 23.91 (-0.83%)
SLB : 46.90 (+2.18%)
$IUXX : 25,304.53 (-1.70%)
ZNH26 : 112-165 (+0.22%)
OXY : 44.70 (+3.21%)
ESH26 : 6,929.25 (-1.04%)
FANG : 154.17 (+1.96%)
$DOWI : 48,921.38 (-0.55%)
SPY : 686.89 (-0.99%)
DIA : 489.22 (-0.55%)
INSM : 164.22 (+0.31%)
2 Nasdaq 100 Stocks Worth Investigating and 1 We Turn Down

2 Nasdaq 100 Stocks Worth Investigating and 1 We Turn Down

TSLA : 435.96 (-2.51%)
VRTX : 448.17 (-1.43%)
EA : 204.28 (-0.02%)
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 44 th Annual J.P. Morgan...

VRTX : 448.17 (-1.43%)
2 Cash-Producing Stocks to Consider Right Now and 1 We Find Risky

2 Cash-Producing Stocks to Consider Right Now and 1 We Find Risky

SPB : 64.48 (+0.83%)
VRTX : 448.17 (-1.43%)
VRT : 169.86 (-1.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 469.93
2nd Resistance Point 466.18
1st Resistance Point 460.42
Last Price 448.17
1st Support Level 450.91
2nd Support Level 447.16
3rd Support Level 441.40

See More

52-Week High 519.68
Fibonacci 61.8% 459.64
Last Price 448.17
Fibonacci 50% 441.09
Fibonacci 38.2% 422.54
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar